It's not dilution. It's the shareholders trading the float

New Post Public Reply Private Reply Replies (2) Message Board
corporatexpress
820
It's not dilution. It's the shareholders trading the float that are causing the PPS to do the 2 step. It's us. It's too much of a temptation to buy at .0001 and sell at .0002 for a nice 100% profit, minus commission, then repeat. If 2 billion are in the float (as of Jan 13, 2018), it only takes a small percentage to make it look like the stock is taking off. But it's not and it won't until revenue is generated and it is verified on a financial report, not some kind of press release. In the OTC, PR's are good for one thing only. To hype the stock. They don't generally result in money exchanging hands and are couched in words like "agreement" and the like. But if an 8-K comes out showing actual revenue, that's gold and you can take that to the bank.

With over 8 billion issued common shares it's easy to look at this as a hopeless whale that will never, short of a pump, make it as a successful business with product that people want. Hence, the bottom feeders that aren't interested in bearings, or e-bikes, or whatever can have a manipulative effect on the stock price. I can't say I blame them. Isn't it everyone's purpose when investing to make money? Buy low, sell high.

There are funds set aside for a share buyback but that won't happen until some kind of revenue stream is established. After all, from a business standpoint, what's the point of buying back and retiring less than half of the shares if you've got creditors that are at the gates? Since we don't have a current 10-K or Q to look at, you have to speculate, or guess. Someone else commented on this but there is probably more than a little truth to it; for the creditors to agree to pushing the debt down the road, Bill must have given them a good enough reason to wait. Maybe they were able to see a ledger that contained e-bike PO's. Who knows. But at least we've got until July before the debt is due and a CEO that is at least trying to do something about that.

If you're wondering how the the authorized has gone from 3 billion to 8 billion in such a short amount of time, read the 10-Q's. Here's an example of convertible debt in the form of notes from page 30 of the last 10-Q:

ITEM 2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

4. On May 12, 2017, we issued 58,187,135 shares of our common stock upon conversion of convertible notes. The issuance was exempt in reliance upon the exemption provided by Rule 4(a)(2) and/or Rule 506 of the Securities Act of 1933.
5. On May 23, 2017, we issued 277,777,778 shares of our common stock upon conversion of convertible notes. The issuance was exempt in reliance upon the exemption provided by Rule 4(a)(2) and/or Rule 506 of the Securities Act of 1933.
6. On July 14, 2017, we issued 420,000,000 shares of our common stock upon conversion of 420_______ shares of our Series A Convertible Preferred Stock. The issuances were exempt in reliance upon the exemption provided by Rule 3(a)(9) and/or Section 4(a)(2) of the Securities Act of 1933
7. On July 18, 2017, we issued 287,547,166 shares of our common stock upon conversion of convertible notes. The issuance was exempt in reliance upon the exemption provided by Rule 4(a)(2) and/or Rule 506 of the Securities Act of 1933.
8. On July 19, 2017, we issued 389,000,000 shares of our common stock upon conversion of 389______ shares of our Series A Convertible Preferred Stock. The issuances were exempt in reliance upon the exemption provided by Rule 3(a)(9) and/or Section 4(a)(2) of the Securities Act of 1933.
9. On September 6, 2017, we issued 324,620,000 shares of our common stock upon conversion of convertible notes. The issuance was exempt in reliance upon the exemption provided by Rule 3(a)(9) and/or Section 4(a)(2) of the Securities Act of 1933.
10. On September 6, 2017, we issued 324,620,000 shares of our common stock upon conversion of convertible notes. The issuance was exempt in reliance upon the exemption provided by Rule 3(a)(9) and/or Section 4(a)(2) of the Securities Act of 1933.
11. On September 7, 2017, we issued 194,500,000 shares of our common stock upon conversion of convertible notes. The issuance was exempt in reliance upon the exemption provided by Rule 3(a)(9) and/or Section 4(a)(2) of the Securities Act of 1933.

That's just shy of 2.3 billion shares. The price of doing business without any substantial form of income. Why is this company still floating after all these years of no revenue? It's Bill. He's got a plan and he's trying to implement it. I think it's gone sideways a little due to funding issues and maybe a little concern on the part of potential clients as to TPAC's ability to produce (no track record) but he's working his way through them. Bill has some pretty good ideas that haven't panned out yet, but probably will. I'll say one thing for him, he's persistent. But after all, isn't that why we're in the OTC? A gamble on what seems to be a good idea that a few thousand dollars invested can result in the big payoff.

It's like a drug. It's us.

Trans-Pacific Aerospace (TPAC) Stock Research Links

TPAC Board Company Profile Buy Rating Time & Sales News Filings Financials
JonnyBGood
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lincoln Educational Services Faces Securities Fraud Suit

Updated Category News Views 3

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

Continue Reading
PhoenixAI and Cloudera's Strategic Partnership Shifts Data Landscape

Updated Category News Views 8

Time to Embrace Change: PhoenixAI Teams with Cloudera Mention the word 'partnership' in the tech space, and it's often as common as a cup of joe at dawn—but this one truly shakes things up. We're talking about PhoenixAI hitching its wagon to Cloudera's startup circus, a merging of fire and steel in AI-driven database management. With PhoenixAI strutting its stuff on the...

Continue Reading
Aviator Nation Teams with NFL for 2026 Collection Launch

Updated Category News Views 6

In a move blending sports with a dash of retro flair, Aviator Nation's dropping its first NFL-licensed collection. They’re looking to serve up a blend of vintage vibes and team spirit. Aviator Nation's New Venture Launching their collection on September 24th, 2026, Aviator Nation takes a dive deeper into sports licensing, after scoring a touchdown (literally!) with an...

Continue Reading
Spotlight on AI-Powered Smart Homes for 2027

Updated Category News Views 6

Gearing Up for the Connected Home Revolution Ah, the thrill of peering into the future of smart homes! That's what's cookin' as Parks Associates gears up for its annual CONNECTIONS™ Conference slated for May 4-6, 2027. This isn't just another routine pow-wow. Nope, this get-together is about seeing who's leading the pack in transforming our everyday spaces into...

Continue Reading
CATL Opens Europe's Largest Battery Service Hub

Updated Category News Views 4

A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...

Continue Reading
Dr. David Lifschutz Honored for Psychiatry Innovation

Updated Category News Views 6

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

Continue Reading
NORD Honors Innovators Shaping Rare Disease Treatment

Updated Category News Views 8

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Continue Reading
AMD CEO, Global Leaders Converge At IMPERIA Summit

Updated Category News Views 4

A Clash of Giants in New York The trade floors are buzzing in New York as the world's economic heavyweights and tech titans gather for the inaugural IMPERIA Summit. You can almost smell the pressure and ambition wafting through the streets when folks like AMD's CEO, Lisa Su, share the stage with geopolitical power players like President Trump and China's President Xi...

Continue Reading
Wrensilva Unveils Studio Console in White Oak

Updated Category News Views 4

The White Oak Revolution Out of San Diego, Wrensilva's giving audiophiles a new reason to tune in: the Studio record console now comes dressed to impress in White Oak. This marks a fresh chapter in their craftsmanship tale, marrying sleek design with the earthy charm of this beloved hardwood. And guess what? The demand for serene home listening setups is peaking like...

Continue Reading
Sequel Advisors Rebrand: Founder-Centric M&A Focus

Updated Category News Views 5

What's in a Name? A Shift to Reflect Reality When a company decides it's time to shake things up with a rebrand, they better have a good reason. Enter what's now called Sequel Advisors—shedding the old label, Transact Capital, to let founders know exactly what they’re dealing with upfront. This isn't just some slick, new logo on a letterhead. It's about aligning their...

Continue Reading

Top 5 Most Recently Viewed Articles

AbbVie's TEPKINLY® Shakes Up Follicular Lymphoma Treatment

Updated Category News Views 10

TEPKINLY®'s Game-Changing Approval Your run-of-the-mill trading day just took a wild turn with AbbVie (NYSE: ABBV) flexing some serious muscle in the oncology space. Their biotech brainchild, TEPKINLY® together with lenalidomide and rituximab (R2), snagged approval from the European Commission to tackle relapsed or refractory follicular lymphoma (FL). This ain't no...

Continue Reading
Bittensor Faces Decline: Analyzing Recent Market Trends

Updated Category News Views 64

Bittensor's Recent Price Movements Bittensor's cryptocurrency, known by its ticker TAO/USD, has faced a notable decline of 6.45% in the last 24 hours, bringing its current price down to $510.45. This drop is part of a broader downward trend that has seen the price decrease by 3.0% over the past week, from $526.14 to its present value. Understanding the Market Dynamics To...

Continue Reading
Tenable's Strategic Move with Apex Security Acquisition to Boost Cyber Defense

Updated Category News Views 353

Empowering Cybersecurity Through Strategic Acquisitions Tenable Holdings, Inc., a leader in exposure management, has recently announced its intention to acquire Apex Security, a cutting-edge company dedicated to securing the increasing vulnerabilities associated with artificial intelligence. This strategic move is primarily aimed at enhancing Tenable's capability to...

Continue Reading
AUGA Group Highlights Resilience Amid Restructuring Measures

Updated Category News Views 199

AUGA Group's Interim Financial Results Reflect Strategic Adjustments AUGA Group, RAB, recently reported its consolidated interim unaudited results for a six-month period. Despite undergoing crucial restructuring phases, the Group successfully reduced costs and improved EBITDA to EUR 6.60 million. Financial Overview for the First Half of 2025 As of September 30, 2025, AUGA...

Continue Reading
Leslies Earnings on the Horizon: Brace for Impact

Updated Category News Views 156

Leslies (NASDAQ: LESL) is about to drop its quarterly earnings on February 17, 2026, and traders are bracing for impact. With estimates landing at an earnings per share (EPS) of $-4.43, the stage is set for volatility. It's a classic 'sell the news' scenario hanging over investors' heads like a dark cloud. The last quarter? A disaster—missed by $1.13, and shares took a...

Continue Reading